Biosimilar eculizumab is available for use in the NHS for the treatment of atypical haemolytic uraemic syndrome. The two biosimilars are Epysqli® (Samsung Bioepis) and Bekemv® (made by Amgen)
Patients with an existing diagnosis of aHUS currently on originator eculizumab can be switched to biosimilar eculizumab.
- There are three brands of eculizumab licensed for aHUS: Bekemv® (Amgen), Epysqli® (Samsung Bioepis), and Soliris® (Alexion).
NHS England recommend all new patients are started on one of the two biosimilar brands of eculizumab (Bekemv or Epysqli) as both provide a significant saving against the cost of the originator brand (Soliris). Ideally, patients on Soliris should be switched to a biosimilar. The choice of biosimilar should be taken at a trust level and be dependent on any use for current patients, licensing differences relevant to some patient cohorts and the understanding that there is the possibility for these prices to change every 12 months (from September/October each year).
There has been extensive analytical characterisation, animal studies and PK/PD studies for both biosimilars however it should be noted that neither biosimilar has undergone a clinical trial in aHUS and comparative studies were performed in paroxysmal nocturnal haemoglobinuria due to the relative ease of studies in PNH vs aHUS
Given that the pathogenesis of both PNH and complement mediated aHUS are mediated through the terminal pathway of complement, the successful trials of the biosimilars have established no clinically meaningful differences in safety, purity, and potency in PNH for which the Soliris is licensed; as such efficacy and safety do not need to be re-established in aHUS.
Switch to biosimilar eculizumab
We believe biosimilar eculizumab is as efficacious as originator eculizumab.
We have been in communication with Amgen and Samsung Bioepis to ensure
- drug availability in new/acute cases – this is discussed further here, in relation to patients with a new diagnosis of aHUS
- logistics regarding switching patients who normally receive their drug in hospital – from originator to biosimilar eculizumab, in the form of a “how to” guide
- logistics regarding switching patients who normally receive their drug via homecare – from originator to biosimilar eculizumab, in the form of a “how to” guide
Further guidance on the process of switching to biosimilar eculizumab are here.